



# HHS Public Access

Author manuscript

*Cell*. Author manuscript; available in PMC 2017 February 01.

Published in final edited form as:

*Cell*. 2017 January 12; 168(1-2): 326. doi:10.1016/j.cell.2016.12.017.

## Retraction Notice to: Betatrophin: A Hormone that Controls Pancreatic $\beta$ Cell Proliferation

Peng Yi<sup>1</sup>, Ji-Sun Park<sup>1</sup>, and Douglas A. Melton<sup>1,\*</sup>

<sup>1</sup>Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Howard Hughes Medical Institute, Harvard University, 7 Divinity Avenue, Cambridge, MA 02138, USA

---

(*Cell* 153, 747–758; May 9, 2013)

In this article, we claimed that Angptl-8, which we termed betatrophin and is also referred to in the literature as TD26, RIFL, C19orf80, and Lipasin, was the agent by which the insulin antagonist S961 induces robust  $\beta$  cell replication in mice. Gusarova et al., in a *Matters Arising* article, subsequently showed that targeted Angptl-8/betatrophin overexpression in mice increases blood triglycerides but does not induce  $\beta$  cell growth (*Cell*, 2014, 159, 691–696). When we repeated our original experiments with a larger number of mice, we also failed to observe  $\beta$ -cell expansion upon Angptl-8/betatrophin overexpression and reported these results in a *Correspondence* (*Cell*, 2014, 159, 467–468). We have subsequently repeated a series of blinded experiments with the Kushner lab and have now determined conclusively that our conclusion that Angptl-8/betatrophin causes specific  $\beta$  cell replication is wrong and cannot be supported (*PLoS One*, 2016, 11, e0159276). Therefore, the most appropriate course of action is to retract the paper. We regret and apologize for this mistake.

---

\*Correspondence: dmelton@harvard.edu.